...

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors

This is a first-in-human, phase 1/2 to learn about the study drug SNS-101.

Why this Research Matters

This study is being conducted in three parts: Part A: Phase 1 Monotherapy Dose Escalation and Dose Expansion (SNS-101 alone) Part B: Phase 1 Combination Dose Escalation and Dose Expansion (SNS-101 in combination with cemiplimab) Part C: Phase 2 Cohort Expansion (SNS-101 alone or in combination with cemiplimab)

Who can Participate

Adult

Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.

Study ID

Protocol Number: 24-0834
More information available at ClinicalTrials.gov: NCT05864144

Meet the Team

Image of Principal Investigator

Sarah Davis, MD

Principal Investigator

Categories

Locations